AVO maintains operational and commercial momentum

Advanced Oncotherapy CEO Nicolas Serandour

Advanced Oncotherapy (AVO) said it had made ‘significant progress’ in its corporate objectives and maintained commercial momentum over the last 12 months despite the Covid-19 pandemic. Announcing its 2020 financial results, CEO Nicolas Serandour said it had been a pivotal year for the company, in which it had signed key commercial partnerships, secured a mix of…

You must be a HM Subscriber to view this content.

Subscribe Now »